Market

The pharmaceutical landscape experienced a seismic shift as investors reacted sharply to the news that the Food and Drug Administration might soon remove major GLP-1 medications from the official shortage list, potentially ending the legal window for telehealth companies to sell compounded versions

A veteran walking into a Department of Veterans Affairs medical center expects the highest standard of care, yet recent investigations suggest that the administrative safeguards designed to protect them are fundamentally broken. The Department of Veterans Affairs faces intense scrutiny as audits

The traditional promise of comprehensive, low-cost medical coverage provided by American corporations has increasingly become a relic of a bygone economic era as organizations adapt to soaring medical expenditures. As medical inflation continues to outpace general economic growth, firms have found

The traditional landscape of drug development is undergoing a massive structural shift as biopharmaceutical companies move away from legacy manual processes toward highly automated, data-driven digital environments. This transition is not merely a matter of convenience but a fundamental necessity

The intricate dance between a virus and its host often hinges on a biological modification so microscopic that it remains invisible until it upends the entire global economy. The transition of animal pathogens into human populations represents one of the most significant threats to modern

The recent failure of the high-profile Phase 3 LAGOON trial involving Zepzelca has sent shockwaves through the oncology community, raising urgent questions about the reliability of surrogate endpoints in modern drug regulation. While the drug initially received accelerated approval based on a